NEW YORK, RAW – Wall Street has ended firmer in a partial rebound from the previous day’s broad sell-off, with remarks from US Federal Reserve Chairman Jerome Powell and the ongoing debt ceiling debate keeping a lid on gains.

The S&P 500 index and the Dow Jones Industrial Average advanced but the Nasdaq Composite closed lower as Treasury yields halted their ascent.

Defensive sectors took the lead as investors sought stability in the volatile market.

Still, all three remain on course to post monthly declines, with the bellwether S&P 500 snapping a seven-month winning streak.

“The same story we’ve seen for a couple of weeks,” said Oliver Pursche, senior vice president at Wealthspire Advisors, in New York.

“Investors are concerned about three things: the eventual taper of bond purchases by the Fed, ongoing inflation with Chairman Powell saying it’s going to stick around longer than initially expected and the debt ceiling issue that congress is grappling with.”

Powell, speaking at a European Central Bank event, expressed frustration over persistent supply chain woes which could keep inflation elevated for longer than expected.

The stock market strengthened following his remarks.

“Powell has been very good at delivering the news officially that everyone knows is coming,” Pursche said.

Wrangling continued on Capitol Hill over funding the government as the Friday deadline to prevent a shutdown approached, with mounting concerns over a US credit default.

US Treasury yields paused after a run-up in recent days as the debt ceiling debate unfolded in Washington DC.

The Dow Jones Industrial Average rose 90.93 points, or 0.27 per cent, to 34,390.92, the S&P 500 gained 6.86 points, or 0.16 per cent, to 4,359.49 and the Nasdaq Composite dropped 34.24 points, or 0.24 per cent, to 14,512.44.

Boeing Co provided the biggest lift to the Dow following China’s aviation regulator’s successful 737 MAX test.

Discount retailer Dollar Tree Inc jumped after increasing its buyback authorisation by $US1.05 billion ($A1.46 billion) to $2.5 billion.

Drug maker Eli Lilly & Co gained on Citigroup’s rating upgrade to “buy” from “neutral”.